List of Diagnostics Companies in Germany - 50

Cardiogenic Shock: the primary circulatory shock in ICUs with a mortality rate over 70%. Triggered by acute myocardial injuries like heart attacks, it leads to severe left-ventricular dysfunction. Despite advancements in care and treatment for up to 200,000 affected U.S. patients annually, the first 30 days after diagnosis see persistently high mortality rates of 50-70%. Understand its pathophysiology, including the critical role of Dipeptidyl Peptidase 3, and the latest interventions.

We are a research-oriented provider of innovative, efficient products and services for early detection, diagnosis and prognosis of autoimmune and infectious diseases, allergies and food intolerances. We strive to improve the diagnosis and management of different diseases as a provider of innovative in-vitro diagnostic products that really work. Built on a tradition of innovation and an interdisciplinary knowledge network, AESKU.DIAGNOSTICS offers unique diagnostic options: faster, more efficient and reliable test systems designed to improve clinical outcomes for the benefit of patients and physicians. Follow us on our other Social Media Profiles. https://www.linkedin.com/company/dst-diagnostische-systeme-&-technologien-gmbh/about/ instagram: https://www.instagram.com/aesku.group/ Contact us: Website: www.aesku.com⁠ E-Mail: socialmedia@aesku.com⁠

ALACRIS Theranostics GmbH is a Berlin-based systems medicine company founded in 2008, originating as a spin-off from the Max Planck Institute for Molecular Genetics. The company focuses on developing innovative solutions in healthcare, particularly in biomarker discovery, drug development, and precision medicine, with an emphasis on molecular oncology. The company offers comprehensive Next-Generation Sequencing (NGS) services that enhance precision medicine. By integrating advanced omics technologies with mechanistic computer modeling, ALACRIS develops biomarkers of drug response. Their services include high-dimensional data analytics and bioinformatics systems, tailored to meet medical needs in collaboration with clinicians. ALACRIS Theranostics is actively involved in partnerships with academia, biotechnology, and pharmaceutical companies, contributing to various research projects and applying their technologies in clinical settings. ALACRIS is committed to delivering data quickly while ensuring quality and confidentiality. Their interdisciplinary team combines expertise in sequencing technologies, advanced computing, and bioinformatics to provide effective healthcare solutions.

Anbio Biotechnology (Anbio) is a leading global medical device company with a focus on in vitrodiagnostics. Our goal is to revolutionize the diagnostics market by personalizing and decentralizingcurrent diagnostic solutions, enabling rapid diagnosis and improving patient prognosis. Weachieve this by offering cutting-edge laboratory, wellness, at-home, and point-of-care (POCT) invitro diagnostic (lVD) solutions that are rapid, accessible, and affordable on a global scale. Since its establishment, Anbio has been committed to delivering the most advanced diagnosticsolutions while ensuring cost-effectiveness for our customers. Our extensive capabilities inresearch and development, manufacturing, and global product distribution logistics allowing us tocontinuously focus on cost reduction while offering a wide range of mature laboratory diagnosticsand point-of-care technology (POCT) products. Our product range spans across cancer, cardio.vascular conditions, pharmacogenomics, hormones, infectious diseases, inflammation, and drugsof abuse tests.

Ariceum Therapeutics is a private clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers. Our lead targeted systemic radiopharmaceutical product, 177 Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic' pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumours and childhood cancer, which currently has few treatment options and a poor prognosis. Ariceum Therapeutics was launched in 2021, following the acquisition of all rights to our lead product from subsequent shareholder, Ipsen. Headquartered in Berlin, Ariceum has operations in Germany and is active across Europe, North America and Australia.

BIORON GmbH is a producer and worldwide acting trader of molecular biological and diagnostic products. Our main focus are ready-to-use solutions for professionals, i.e. high concentrated polymerases for lyophilisation.

BIOTYPE is an innovative German solution provider for molecular precision diagnostics. We are committed to advancing precision medicine through our products & services for reliable analysis and interpretation of clinical biomarkers. BIOTYPE offers a strong portfolio in molecular cancer diagnostics for applications in hemato-oncology, liquid biopsy, and molecular profiling of solid tumors. The portfolio includes IVD assays for clinical diagnostics and RUO assays for translational and clinical research. In addition, BIOTYPE offers high-quality and IVD-compliant contract development and manufacturing services. Our proprietary MODAPLEX platform is a benchtop system for automated molecular profiling and multi-biomarker testing. MODAPLEX addresses the growing need to simplify and accelerate precision testing by reliably delivering actionable molecular information required for biomarker-guided care in precision medicine. The MODAPLEX consolidates multi-gene testing into one workflow with same-day results. BIOTYPE‘s quality management system is certified according to ISO 9001:2015 & ISO 13485:2016.

Home of the BLINK Beads, the BLINK X and the BLINK One. BLINK is revolutionizing the field of bioanalytics and diagnostics. We have created next-generation microfluidics-free digital PCR technology that combines sample nucleic acid extraction, multiplex analysis and quantification in a single compact workflow. Our rapid, ultra-sensitive digital multiplex assays empower scientists and clinicians to make high-impact discoveries and enables rapid molecular diagnostics to achieve an immediate, targeted therapy, ultimately leading to better patient outcomes and a more effective healthcare system.

Bosch Healthcare Solutions (BHCS) is a wholly owned subsidiary of Robert Bosch GmbH and was founded in 2015. We create innovative diagnostic solutions to improve people's quality of life and global healthcare. BHCS unites the innovative mindset of a young company with the leading expertise and quality claim of the Bosch brand. We tailor our products and services to the needs of our customers in order to continuously optimize the user experience. Our vision is to make healthcare routines a little better and easier every day. This motivates our interdisciplinary teams to pursue excellence. Corporate information: bosch-healthcare.com/en/corporate-information/ Privacy Policy: bosch-healthcare.com/en/data-privacy/

We are a world leader in gene analyses for a wide range of medical, research and pharmaceutical applications. Since 2009, we have been helping doctors and patients find the genetic causes of rare diseases. We provide researchers and pharmaceutical companies with genetic analysis for clinical trials and medical innovation. We help oncologists and cancer patients find the best therapy option. We continue to drive science forward with our own insights. You can find our imprint under the following link: https://www.cegat.de/en/disclaimer/ Sie finden unser Impressum unter folgendem Link: https://www.cegat.de/impressum/

CELLphenomics is a thriving and diverse place to work and learn. We offer fee-for-service research as well as research projects with academic partners on the local, national and EU level. Our partners, clients and staff, with representation from more than 20 countries, are brought together by the common goal of translational research.

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.

Cerca Biotech is a medical diagnostic company focused on bringing innovative solutions to oncology and women’s health. We strive to introduce the best tests to meet clinical needs at an affordable cost, with accuracy and rapid results at the core. Our focus is MammaTyper®, a reverse transcription-quantitative polymerase chain reaction PCR (RT-qPCR) assay and the first real innovation in breast cancer diagnostics for decades. MammaTyper® applies 21st century techniques to breast cancer subtyping, ensuring that every tissue sample is tested reliably, accurately, and quickly.

Founded in 2007, Curetis is a molecular diagnostics company whose mission is on the development and commercialization of reliable, fast and cost-effective syndromic testing products for the diagnosis of severe infectious diseases. The diagnostic solution Unyvero of Curetis enables rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with the conventional techniques. The Unyvero diagnostic platform can be used for the diagnosis of hospitalized patients with several applications with the broadest panels to detect pathogens as the HPN (Hospitalized Pneumonia), BCU (Blood Culture Infection), ITI (Implant & Tissue Infections), IAI (Intra-Abdominal Infections) and UTI (Urinary Tract Infections). The company is based in Holzgerlingen near Stuttgart, Germany and all the products are fully developed and produced in Germany. Curetis has entered into several international distribution agreements covering many countries across Europe, USA, the Middle East and Asia. Imprint: http://www.curetis.com/en/impress.html

Devyser. A new level of certainty We’re specialists when it comes to diagnostic kits for complex DNA testing within oncology, hereditary diseases and transplantation. Our products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics, as well as in post transplant follow-up. We have a guiding principle when it comes to developing products that are ideal for routine diagnostics: make the technology simple, reproducible and less prone to user-generated errors. And this is precisely what our customers appreciate about us, which is why routine diagnostic laboratories in more than 60 countries worldwide use our products.

Awarded for "most innovative German startup" from German business magazine Bilanz, DiaMonTech has developed a medical device that non-invasively measures your blood glucose without finger pricking, a drop of blood, or a test strip. Simply relax your fingertip on the sensor, wait 5 to 15 seconds, and your blood glucose level will be displayed. Our patented technology works with an invisible infrared light beam that looks into your skin and counts glucose molecules. Diabetes is a global challenge. More than 400 million people worldwide suffer from the disease. Our goal is to make checking your blood glucose level as easy as unlocking your phone. You will be able to get measurements throughout the day without pain or extra costs. Diabetologists suggest that more frequent blood glucose measurements can lead to better overall diabetes management and less diabetes-related illnesses. Until there's a cure for diabetes, DiaMonTech can make living with it much easier.

Choosing Quality. DiaSys Diagnostic Systems emerged as pioneer in the field of liquid stable reagents and has developed to an established provider of diagnostic solutions for the clinical laboratory. DiaSys develops, manufactures and markets diagnostic systems of superior quality. Laboratories, hospitals, and physicians in more than 100 countries rely on DiaSys products and services for the well-being of their patients. Since its foundation in 1991, the independent company has introduced more than ninety liquid-stable reagents for routine and special diagnostics completed by calibrators and controls. The instrumentation portfolio comprises partially and fully automated analyzers for small and medium-sized laboratories. Additionally, DiaSys provides devices and rapid tests for the point of care. Permanent update of quality products and processes and tailor-made solutions along with strong customer support maintain and extend DiaSys’ position as top quality supplier. In order to be close to the customer, DiaSys is continuously extending its global sales and support network; discover DiaSys’ activities all over the world. Impressum: https://www.diasys-diagnostics.com/misc/legal-notice/ Privacy Policy https://www.diasys-diagnostics.com/misc/privacy-policy/

Epigenomics is a molecular diagnostics company focused on the development of blood-based DNA methylation tests for the early the detection of cancer. The Epi proColon test has recently become the first and only FDA approved blood test for colorectal cancer screening. Epi proColon, HCCBloodTest, and the Epi proLung tests are available in Europe as CE-marked IVDs. Industry partners, as well as the medical and life science communities, can access our expansive intellectual property portfolio. Epigenomics has been granted over 60 patents, in addition to many others that have been filed. These patents cover DNA methylation technologies and biomarkers, as well as our DNA methylation expertise through research products, biomarker services, IVD development collaborations, and licensing.

EUROIMMUN'un uzmanlık alanı immünoloji, hücre biyolojisi, histoloji, biyokimya ve moleküler biyolojidir. Otoimmün ve enfeksiyöz hastalıkların, alerjilerin ve gen analizlerinin laboratuvar tanısı için test sistemleri üretir. Hasta numunelerinde antikorların tespiti için test sistemleri ön planda olmakla birlikte, antijenler ve genetik markerlar da mevcuttur. Bunlar, indirekt immünofloresan, mikrotitreli ELISA'lar ve farklı blot teknikleri (Westernblot, EUROASSAY, EUROLINE, EUROLINE-WB) ve moleküler biyolojik (mikroarray) teknikler gibi immünohisto-kimyasal ve biyokimyasal yöntemlere dayanmaktadır. EUROIMMUN üretimini, dünya çapında patentleri taşıyan modern, son teknoloji prosedürleri ve mikroanaliz tekniklerine dayandırır. Şirket, tıbbi laboratuar teşhis ürünlerinin lider üreticilerinden biridir. Ürünlerimiz Avrupa, Amerika, Asya, Avustralya ve Afrika'da yaklaşık 130 ülkede kullanılmaktadır.   Aralık 2017 itibariyle, Amerikan PerkinElmer firması, EUROIMMUN hisselerinin çoğunluğunu elinde tutmaktadır. PerkinElmer medikal ve biyoteknoloji alanında uluslararası bir liderdir. Yenilikçi tespit ve görüntüleme teknikleri ve IT sistemleri ile, teşhis, tıbbi araştırma, çevre ve gıda analizlerinde kapsamlı uzmanlık sağlar.

Hain Lifescience GmbH is a manufacturer and distributor of in-vitro diagnostics based in Nehren in the district of Tübingen.

Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Former clinical assets MESUPRON® and REDECTANE® have been partnered. Our mission is to research and develop therapies for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.

Hummingbird extracts deep insights into disease through the integrated analysis of both disease and immune system derived small RNA biomarkers from whole blood. This dual interrogation of signal from disease and the host response to disease enables a highly sensitive, robust, and AI powered platform that will revolutionize how we diagnose, treat, and manage cancer and other diseases.

Immundiagnostik – Closing the Gaps in Laboratory Diagnostics Immundiagnostik AG, founded in 1986, is a globally operating diagnostics company represented in over 30 countries. We focus on the development and production of innovative immunoassays (ELISA, EIA) and other analytical detection methods (e.g. HPLC and PCR) for medical routine and research. Furthermore, we offer a broad portfolio of antibodies and antigens. Our business relations include contract analyses for diagnostic laboratories and academic research institutions, esp. in context with clinical trials. Multiple cooperations with the pharmaceutical industry and a tight network with scientific organisations are the basis of a successful product development. Securing progress: Our comprehensive range of products is continuously refuelled by a rich pipeline of proprietary developments. With a headcount of more than 50 employees, Immundiagnostik's headquarter is located in Bensheim, south-western Germany.

PASSION FOR PRECISION. ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radioisotopes and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor α positive tumors like lung, ovarian or breast cancer. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. For more information please visit: www.itm-radiopharma.com. Please see our Community Guidelines: https://isotope-technologies-munich.com/service/community-guidelines

Mainz Biomed (NASDAQ: MYNZ) was founded in Germany and is becoming a leading molecular genetic diagnostics company developing market-ready molecular genetic diagnostic solutions. The company's goal is to place effective solutions in the hands of those who need them, with a focus on medical revolutions in diagnostic technology. Mainz Biomed offers genetic and genomic tests that identify the unique genetic profile of individual patients, as well as in-vitro diagnostic tests for the early detection of cancer in the United States.

At midge medical, we're reimagining the way healthcare systems work. We create the future of diagnostics by making medical testing available to everyone. midge medical is developing diagnostic devices based on blood and other body fluids that are so easy to operate that they can be used by consumers as well as by health care professionals. The complete digitization of the testing procedure is at the core of our vision. We believe testing should be available, accessible and affordable to all. With our aim for ubiquitous testing, we will create a healthier world, reduce infections and take the pressure off public medical resources. Legal imprint: https://cutt.ly/midgeimprint Privacy policy: https://cutt.ly/midgeprivacy

Mindpeak's mission is to enable personalised cancer treatment through AI tissue diagnostics Our partners are leading pathology and university labs. Our team consists of world-class industry experts in machine learning and company building. Mindpeak's Impact The demand for medical image analysis is growing rapidly but the number of cancer experts remains the same - this results in growing workloads per specialist. We help cancer experts meet this challenge. We build automation tools for visual diagnosis using state-of-the-art artificial intelligence and deep learning. Our tools assist cancer experts in providing reliable and reproducible diagnoses. This frees specialists from tedious, repetitive tasks such as quantification of cells or biomarkers and allows them to focus on tasks where their human expertise is indispensable.

MODAG focuses on research and development of therapeutics and diagnostics for neurodegenerative diseases. It is a privately held company located at the Hochtechnologiepark Wendelsheim, Germany with additional Research & Development facilities in Munich and Göttingen. MODAG’s innovative approach offers a unique combination of early diagnosis and targeted disease-modifying therapies for severe neurological disorders. MODAG´s collaborations with top-tier US and European research institutions, combined with the interdisciplinary research and development expertise of the founder´s and the management team, provide ideal conditions for the accelerated implementation into clinical applications. Built upon an extensive portfolio of patented active compounds, MODAG is developing a new oligomer modulator for Multiple System Atrophy (MSA) and other synucleinopathies such as Parkinson´s disease (PD) with the potential to deliver novel disease-modifying, first-in-class drugs with the potential to halt progression.

Molzym is a developer and manufacturer of innovative products for molecular microbiology and microbial pathogen diagnostics. Products range from pre-analytical kits for the enrichment and extraction of microbial DNA to analytical PCR kits with ultra-clean DNA-free reagents and are distributed in more than 30 countries worldwide. MolYsis™ is Molzym's proprietary technology of human DNA removal and targeted isolation of microbial DNA from a variety of liquid and tissue samples including whole blood, CSF, BAL, joint aspirates, tissue biopsies, abscesses and other materials. Molzym's ultra-clean PCR and real-time PCR assays, targeting the 16S/18S genes, allow detection, even at low amounts, and identification down to species level with subsequent sequencing. In addition, Molzym offers CE IVD-marked solutions for the culture-independent detection of pathogens in clinical diagnostics. Manual DNA isolation can be accomplished with SepsiTest™-UMD and with Micro-Dx™ the process is performed fully automated on the SelectNA™plus instrument. It combines highest technical advances with demands for contamination-free and low-hands-on processing of samples. This together with the extremely active broad-range PCR or Real-Time PCR followed by sequencing analysis enables the sensitive detection and identification of pathogens. Learn more about microbial enrichment, manual and automated solutions, molecular diagnostics and NGS and get an inside view on Molzym - read our blog at https://www.molzym.com/molzym-blog.

multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform on the basis of the founding scientists'​ (Professor Gabriele Multhoff, Dr Claus Botzler) discovery that cell surface-bound Hsp70 is uniquely expressed on a large proportion of cancers (~50-75%), but not on healthy cells. This makes this form of Hsp70 an excellent and broadly-applicable molecule on which to base the development of innovative therapeutics and diagnostics (theranostics). Based on its discovery of membrane Hsp70, multimmune has succeeded in developing a powerful pipeline of cancer therapeutics. ENKASTIM allows, for the first time, a unique and specific activation of human natural killer (NK) cells which are programmed to recognise and kill cancers expressing membrane Hsp70 via the release of a cytotoxic molecule called granzyme B. These cells destroy tumors and metastases that are invisible to the cell killing (cytolytic) consequences of more conventional T cell-based immunotherapies. Hsp70-expressing tumors can also be targeted using therapeutics based on a unique monoclonal antibody which can detect the membrane form of Hsp70. multimmune's lead diagnostic candidate is the patented and CE-marked Hsp70-exo enzyme immunoassy (ELISA) which detects lipid-associated Hsp70 in the peripheral circulation, levels of which can be used to detect the presence of tumors expressing membrane Hsp70, as well as monitoring therapeutic response and disease recurrence.

Noscendo GmbH, a Duisburg (Germany) based molecular diagnostics company, changes the way infection causative microbes are identified. Introducing a paradigm shift using proprietary algorithms and software harnessing next generation sequencing of cell free nucleic acids isolated from patient samples Noscendo brings the concept of liquid biopsy into the field of infectious diseases. Noscendo’ s software solution is capable of differentiating infection from non-infectious signals and thereby aiding intensive care clinicians in their daily task to find the right decisions, enabling a targeted and successful treatment in an actionable timeframe.

oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.

The cell-screening you know, now made affordable! With Oncolead you can easily test your compounds over 80+ of human cell-lines in a four-weeks time. We have run our processes for more than 75+ projects in cooperation with big pharma, and we aim to bring our services even to the smallest lab around the world. We know how to do cell-screening and deliver reliable, reproducable and fast results, and we do it with a transparent and competitive pricing model.

ORGENTEC Diagnostika based in Mainz, Germany, is a diagnostics company, focused on automation of laboratory tests in the fields of autoimmunity and infectious diseases. Enzyme linked immunosorbent assays (ELISA), immunoblots and immunofluorescence assays are "made in Germany" - with research and development, production and distribution from Mainz to over 100 countries.

Origenis - We cure diseases with novel small molecule drugs where no drugs have been discovered yet. We create synergistic small molecule drug pipelines.

Siemens Healthineers is a leading medtech company with over 125 years of experience. We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Our portfolio, spanning in vitro and in vivo diagnostics to image-guided therapy and cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the greatest challenges in healthcare. We will continue to build on these strengths to help overcome the world's most threatening diseases, enable efficient operations, and expand access to care. We are a team of more than 71,000 Healthineers in over 70 countries passionately pushing the boundaries of what is possible in healthcare to help improve the lives of people around the world.

Our commitment to scientists is to support them in making new scientific discoveries and groundbreaking research within the life sciences and gene therapy. It is our underlying mission, to help progress new therapies safely, quickly and affordably, so together we can provide solutions to people suffering from poor health and affected by disease every day. PROGEN is made up of a team of experts within AAV and the life sciences and is partnered with gene therapy experts worldwide. We are more than just a manufacturer of antibodies, proteins and ELISAs kits. We strive to understand what scientists need, so we can create solutions and ultimately deliver high quality antibody and exclusive AAV products, which solve your research challenges within academia, biotech and pharma, and ensure PROGEN can continue to be a trusted and reliable partner. Visit our website www.progen.com Imprint: https://bit.ly/3uEZf2h Privacy Statement: https://bit.ly/3dMSgxm

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31 2021 QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.

ROTOP Pharmaka is a leading German pharmaceutical company that produces cGMP compliant radiopharmaceuticals for diagnostics and therapy in Nuclear Medicine and Molecular Imaging and distributes them in more than 30 countries worldwide. With almost 20 years of experience in the development, production, authorization and distribution of sterile kits for radiolabeled pharmaceuticals ROTOP continuously expands its product portfolio by developing new products and entering new strategic partnerships.

ROXALL Group is an international pharmaceutical company based in Hamburg, Germany. Our core business is pharmaceuticals for allergen immunotherapy – the only causal allergy therapy renowned by the World Health Organization (WHO) that not only has the capacity to prevent an allergy turning into asthma but can also block the growth of new sensitizations. At ROXALL, we strive to constantly improve our treatments and to manufacture the highest quality products. As a result, we have made several and many of the most important innovations in this field. ROXALL Group has subsidiaries in Europe, Asia and Latin America. The acquisition of the allergy-line of a pharmaceutical company in Bilbao, Spain, opened us a solid basis for future growth. Research in immuno- therapy has been the main focus of this company for more than 70 years. Our team in Bilbao works closely with leading research institutes, providing us with greater potential for developing new treatments. In addition to our allergen immune therapies, our subsidiary company DR. BECKMANN Pharma offers medical products that help ease many allergy symptoms. Our products range from nasal showers and ointments for sensitive skin to high quality allergen encasings and peak-flow meters.

[INTRODUCING OUR COMPANY] The people of Seegene are on a purposeful mission to improve the world we live in. We aim to improve the quality of life for everyone globally by bringing molecular diagnostics to the masses. Molecular diagnostics is the most effective method to accurately diagnose ailments and is also the best way to diagnose them early which is when you can make the most difference in the recovery treatment. With industry-leading IP in molecular diagnostics reagent assays, we are dedicated to leveraging our unique technologies to increase our product portfolio, expand our market coverage, and lowering the total cost to serve our customers so that molecular diagnostics become a part of the fabric of everyone’s life and thus, improving the quality of life for everyone in the world. [OUR HISTORY AND OUR FUTURE] Since our founding in 2000, we have been steadfastly focused on molecular diagnostics. Currently, our product portfolio consists of over 250 molecular diagnostics reagent kits as well as a wide range of instruments and consumables that are sold globally. Testament to our expertise, when the pandemic started, Seegene was one of the first companies in the world to provide testing kits that were crucial in the fight against COVID. Today, we are a company with revenue of over $1 billion dollars and 65% gross margins. With 8 overseas entities, we generate a majority of our revenue outside of Korea. In keeping with our spirit of innovation and making a difference in the world, there are many exciting innovations being worked on at Seegene which will make it easier for the world to access the benefits of molecular diagnostics. We are transforming our business from a discrete reagent assay and instruments business to a platform business that will create new markets for molecular diagnostics and improve the quality of life for everyone. We hope that you will join us in our mission to make a meaningful difference in the world.

Headquartered in Burlington, MA, for 40 years SEKISUI Diagnostics has been committed to helping improve the lives of patients by providing innovative medical diagnostics to physicians and laboratories. We continue to invest in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems, and have a leading position as a provider of rapid tests in the US and high throughput coagulation systems in Japan. Our workforce spans six sites located in four countries. We are a sister company to SEKISUI Medical in Japan, making us a worldwide company with R&D and Manufacturing facilities on three continents. We develop, manufacture, and supply billions of tests each year to the global healthcare market through our commercial networks and partners. Our product lines include: • Clinical chemistry reagents • Coagulation reagents • Point-of-care rapid tests and immunoassay system • Enzymes and specialty biochemicals

SensID is specialized in the design and manufacturing of Reference Material for DNA diagnostic procedures. Our reference material is manufactured under the highest standards in the world. The products are especially designed and suitable for R&D, Validation, external control, preparation of accreditation processes, round robin tests, as part of your diagnostic device or kit and whatever you can imagine. We provide: gDNA, cfDNA/ctDNA, cfDNA/ctDNA in Plasma, FFPE tissue and slides with defined allelic frequency and 100% defined sequence, defined mixing ratio of wt/mut cells and more for use in PCR, Sequencing, or any application you can imagine. For further information, please contact us under: info@sens-id.com

At SOMATEX®, we are dedicated to improving healthcare by providing high quality solutions every day. For more than 25 years, we have brought new products and technologies to the world, especially in the fields of breast care, soft tissue and bone marrow biopsy, pulmonary interventions, fetal therapy, assisted reproduction and radiation protection. Thanks to exceptional innovations, we have set new standards in women's health. We are committed to meet the needs of patients, clinicians and practitioners to enable better diagnostics and therapies and improve the standard of care. Today, SOMATEX® products are used around the world in university clinics, hospitals, breast centers and medical practices to continuously improve the quality of patients' life. Our growth is driven by the strength of our research and development capability, highly qualified employees that share our vision and values, and our strong network of partners. For more information visit our website: www.somatex.com

SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies. SphingoTec GmbH was established in 2002 by Dr. Andreas Bergmann was one of the founders of B.R.A.H.M.S. AG. As former Chief Research Officer, he was responsible for the development of the "gold standard" sepsis biomarker Procalcitonin (B.R.A.H.M.S. PCT™).

The highly experienced research team founding the STRATIFYER Molecular Pathology GmbH has developed techniques to analyze routine tumor material for sophisticated molecular analysis. A specialized process has been developed that guarantees fast and reliable assessment of prognostic and predictive gene signatures in mid-throughput fashion. This technology has been exploited for multiple years to enable in-depth genomic research accompanying large clinical trials. First pathology labs have been powered by STRATIFYER Molecular Pathology GmbH to integrate RNA expression profiling tests in clinical routine. The molecular STRATIFYER test systems shall enable physicians to optimize anti-cancer treatment at patient's initial diagnosis according to individual differences of the tumors.

SYNLAB Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporates. SYNLAB operates in 30+ countries across four continents. More than 27,000 employees, including over 2,000 medical experts, contribute every day to the Group’s worldwide success.

Better breast cancer screening should be a universal offering to every woman in the world. Vara’s AI-powered software platform, created with screening radiologists within the German Mammography Screening Programme, mitigates much of the human subjectivity associated with reading mammography results—and reduces the repetitive work screening physicians are routinely subjected to. Vara’s full-stack platform manages all processes within a screening centre and makes breast cancer screening more effective, more measurable, and more accessible for everyone, everywhere. By democratising access to early screening around the world, we deliver measurable impact backed by clinical evidence. We are partnering globally, to deliver breast cancer screening where it is needed most.

Who are we? vermicon AG from Munich, Germany, specializes in the development and production of sustainable solutions for the industrial microbiology. Since 1997, our actions are guided by the credo that the conventional limitations of microbiology have to be broken down in order to receive convincing solutions. Successful answers for microbiological challenges and a permanent implementation of these solutions into practice is what we strive for. What are we offering? PRODUCTS Detection systems and test kits for industrial customers. Handy and suitable for on-site application, fast and nevertheless highly specific results. Simple workflow. Microbiology in a standardized and industrialized shape. SERVICES
 Comprehensive analyses for microbiology – fast, reliable and flexible. Our technology allows us to deliver insights and results that cannot be achieved with conventional methods. MICROBIOLOGICAL CONSULTING 
A unique combination of microbiology and consulting. Break new ground with us! Even for national or international research projects, we are your reliable partner. We bring our great wealth of experience to bear in every new project and every new problem. A broad spectrum of technological options and a high innovative capacity guaranteed by a team of microbiologists and chemists allow us to always break new and exciting ground. Learn more about us – our corporate principles say it all: ...to provide unique and efficient solutions for microbiology ...to meet successfully microbiological challenges which no one has solved before.

INSPIRED BY DEDICATION - that was our credo right from the start and we want to live up to this claim in the future as well! For more than four decades now, Virion\Serion has proven to be a reliable, competent and trusted partner for our customers worldwide. All processes, services and products are managed in accordance with the EU directive 98/79/EG, under a certified quality management system according to DIN EN ISO 13485, to ensure and maintain the highest quality of our products and services. All products are manufactured in Wuerzburg and distributed worldwide.